Literature DB >> 24211771

Purification and biological characterization of soluble, recombinant mouse IFNβ expressed in insect cells.

Sebastian A Stifter1, Jodee A Gould2, Niamh E Mangan3, Hugh H Reid4, Jamie Rossjohn5, Paul J Hertzog6, Nicole A de Weerd7.   

Abstract

Interferon β (IFNβ) is a member of the type I interferon family of cytokines widely recognised for their anti-viral, anti-proliferative and immunomodulatory properties. Recombinant, biologically active forms of this cytokine are used clinically for the treatment of multiple sclerosis and in laboratories to study the role of this cytokine in health and disease. Established methods for expression of IFNβ utilise either bacterial systems from which the insoluble recombinant proteins must be refolded, or mammalian expression systems in which large volumes of cell culture are required for recovery of acceptable yields. Utilising the baculovirus expression system and Trichoplusia ni (Cabbage Looper) BTI-TN-5B1-4 cell line, we report a reproducible method for production and purification of milligram/litre quantities of biologically active murine IFNβ. Due to the design of our construct and the eukaryotic nature of insect cells, the resulting soluble protein is secreted allowing purification of the Histidine-tagged natively-folded protein from the culture supernatant. The IFNβ purification method described is a two-step process employing immobilised metal-ion affinity chromatography (IMAC) and reverse-phase high performance liquid chromatography (RP-HPLC) that results in production of significantly more purified IFNβ than any other reported eukaryotic-based expression system. Recombinant murine IFNβ produced by this method was natively folded and demonstrated hallmark type I interferon biological effects including antiviral and anti-proliferative activities, and induced genes characteristic of IFNβ activity in vivo. Recombinant IFNβ also had specific activity levels exceeding that of the commercially available equivalent. Together, our findings provide a method for production of highly pure, biologically active murine IFNβ.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biologically active; Endotoxin-free; Insect cell expression; Interferon beta; Natively folded; Soluble protein

Mesh:

Substances:

Year:  2013        PMID: 24211771     DOI: 10.1016/j.pep.2013.10.019

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  10 in total

1.  Defining the distinct, intrinsic properties of the novel type I interferon, IFNϵ.

Authors:  Sebastian A Stifter; Antony Y Matthews; Niamh E Mangan; Ka Yee Fung; Alexander Drew; Michelle D Tate; Tatiana P Soares da Costa; Daniel Hampsey; Jemma Mayall; Phil M Hansbro; Albert Garcia Minambres; Sahar G Eid; Johnson Mak; Judy Scoble; George Lovrecz; Nicole A deWeerd; Paul J Hertzog
Journal:  J Biol Chem       Date:  2017-11-29       Impact factor: 5.157

2.  Production of biologically active feline interferon beta in insect larvae using a recombinant baculovirus.

Authors:  Mariana Bernadett Arregui; Gregorio Juan Mc Callum; Ignacio Smith; Marcela Solange Villaverde; Federico Javier Wolman; Alexandra Marisa Targovnik; María Victoria Miranda
Journal:  3 Biotech       Date:  2018-07-27       Impact factor: 2.406

3.  Production and characterization of thirteen human type-I interferon-α subtypes.

Authors:  Srilalitha Kuruganti; Mary Ann Accavitti-Loper; Mark R Walter
Journal:  Protein Expr Purif       Date:  2014-08-20       Impact factor: 1.650

4.  The structure of the atypical killer cell immunoglobulin-like receptor, KIR2DL4.

Authors:  Shoeib Moradi; Richard Berry; Phillip Pymm; Corinne Hitchen; Simone A Beckham; Matthew C J Wilce; Nicholas G Walpole; Craig S Clements; Hugh H Reid; Matthew A Perugini; Andrew G Brooks; Jamie Rossjohn; Julian P Vivian
Journal:  J Biol Chem       Date:  2015-03-10       Impact factor: 5.157

5.  A hot spot on interferon α/β receptor subunit 1 (IFNAR1) underpins its interaction with interferon-β and dictates signaling.

Authors:  Nicole A de Weerd; Antony Y Matthews; Phillip R Pattie; Nollaig M Bourke; San S Lim; Julian P Vivian; Jamie Rossjohn; Paul J Hertzog
Journal:  J Biol Chem       Date:  2017-03-13       Impact factor: 5.157

6.  A proline deletion in IFNAR1 impairs IFN-signaling and underlies increased resistance to tuberculosis in humans.

Authors:  Guoliang Zhang; Nicole A deWeerd; Sebastian A Stifter; Lei Liu; Boping Zhou; Wenfei Wang; Yiping Zhou; Binwu Ying; Xuejiao Hu; Antony Y Matthews; Magda Ellis; James A Triccas; Paul J Hertzog; Warwick J Britton; Xinchun Chen; Carl G Feng
Journal:  Nat Commun       Date:  2018-01-08       Impact factor: 14.919

7.  miR-222 isoforms are differentially regulated by type-I interferon.

Authors:  Charlotte Nejad; Katherine A Pillman; Katherine J Siddle; Geneviève Pépin; Minna-Liisa Änkö; Claire E McCoy; Traude H Beilharz; Lluís Quintana-Murci; Gregory J Goodall; Cameron P Bracken; Michael P Gantier
Journal:  RNA       Date:  2017-12-20       Impact factor: 4.942

8.  Killer cell immunoglobulin-like receptor 3DL1 polymorphism defines distinct hierarchies of HLA class I recognition.

Authors:  Philippa M Saunders; Phillip Pymm; Gabriella Pietra; Victoria A Hughes; Corinne Hitchen; Geraldine M O'Connor; Fabrizio Loiacono; Jacqueline Widjaja; David A Price; Michela Falco; Maria Cristina Mingari; Lorenzo Moretta; Daniel W McVicar; Jamie Rossjohn; Andrew G Brooks; Julian P Vivian
Journal:  J Exp Med       Date:  2016-04-04       Impact factor: 14.307

9.  Modified Polyadenylation-Based RT-qPCR Increases Selectivity of Amplification of 3'-MicroRNA Isoforms.

Authors:  Charlotte Nejad; Geneviève Pépin; Mark A Behlke; Michael P Gantier
Journal:  Front Genet       Date:  2018-01-24       Impact factor: 4.599

10.  Activation of cGAS-dependent antiviral responses by DNA intercalating agents.

Authors:  Geneviève Pépin; Charlotte Nejad; Belinda J Thomas; Jonathan Ferrand; Kate McArthur; Philip G Bardin; Bryan R G Williams; Michael P Gantier
Journal:  Nucleic Acids Res       Date:  2016-09-29       Impact factor: 16.971

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.